
Stryker, Boston Scientific, and McKesson are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare, such as pharmaceutical and biotech firms, medical-device makers, and healthcare providers. Their performance can be affected by factors including research results, regulation, patent protection, and demand for medical services and products. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Stryker (SYK)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Shares of NYSE SYK traded up $1.61 during trading on Monday, hitting $311.25. The company had a trading volume of 1,041,758 shares, compared to its average volume of 2,514,251. The stock has a 50 day simple moving average of $292.30 and a 200 day simple moving average of $322.60. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18. Stryker has a 12 month low of $267.00 and a 12 month high of $389.33. The firm has a market capitalization of $118.49 billion, a P/E ratio of 33.16, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78.
Read Our Latest Research Report on SYK
Boston Scientific (BSX)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Shares of NYSE:BSX traded down $0.36 during mid-day trading on Monday, reaching $43.98. 5,752,838 shares of the company traded hands, compared to its average volume of 18,662,734. The company’s 50 day moving average price is $44.00 and its 200-day moving average price is $54.50. The firm has a market cap of $63.75 billion, a PE ratio of 18.66, a PEG ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81. Boston Scientific has a 52 week low of $39.57 and a 52 week high of $102.71.
Read Our Latest Research Report on BSX
McKesson (MCK)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
NYSE MCK traded up $3.67 on Monday, reaching $1,106.48. 222,209 shares of the stock were exchanged, compared to its average volume of 907,480. McKesson has a one year low of $723.68 and a one year high of $1,121.50. The firm has a market capitalization of $127.75 billion, a PE ratio of 28.41, a PEG ratio of 1.86 and a beta of 0.27. The company’s 50-day simple moving average is $955.45 and its two-hundred day simple moving average is $874.53.
Read Our Latest Research Report on MCK
See Also
- MarketBeat’s Top Five Stocks to Own in November 2026
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
